Exploratory Digital Outcome Measures of Motor Sign Progression in Parkinson’s Disease Patients Treated with Prasinezumab
7 Articles
7 Articles
Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab
Digital health technology (DHT) tools for Parkinson’s disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab. 316 early-stage PD participants were randomized to placebo, 1500 mg, or 4500 mg prasinezumab for 52 weeks; placebo participants were re-randomized to prasinezumab for the ensuing 52 weeks. Patients…
Roche advances treatment for Parkinson’s disease - Pharmafile
Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, an investigational therapy for Parkinson’s disease. This decision is influenced by positive data from the phase 2b PADOVA study, ongoing open-label extensions (OLEs) of PADOVA as well as phase 2 PASADENA studies. Multiple endpoints from the PADOVA and OLE studies […] The post Roche advances treatment for Parkinson’s disease appeared first on Pharma…
Belgium-based Koios Care lands €1M
Antwerp-based Koios Care has secured €1M in seed funding led by Evercurious VC to advance its AI-powered platform for Parkinson’s disease monitoring and care. Founded by Dr. Konstantinos Kyritsis and Dr. Dimitris Iakovakis in 2022, the health tech startup transforms passive data from everyday smartphones and smartwatches into actionable clinical insights. The funding will support crucial steps in regulatory clearance, market commercialisation, a…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression Parkinson’s disease affects over 10 million people globally and significant unmet need remains Basel, 16 June 2025 […] The post Roche to advance prasin…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium